当前位置: X-MOL 学术Blood Cancer J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Blood Cancer Journal ( IF 12.8 ) Pub Date : 2022-05-31 , DOI: 10.1038/s41408-022-00684-8
Vanessa Piechotta 1 , Sibylle C Mellinghoff 2, 3 , Caroline Hirsch 1 , Alice Brinkmann 1 , Claire Iannizzi 1 , Nina Kreuzberger 1 , Anne Adams 4 , Ina Monsef 1 , Jannik Stemler 2, 3 , Oliver A Cornely 2, 3, 5 , Paul J Bröckelmann 2, 6 , Nicole Skoetz 1
Affiliation  

The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM) appears limited due to disease and treatment-associated immune impairment. We conducted a systematic review of prospective studies published from 10/12/2021 onwards in medical databases to assess clinical efficacy parameters, humoral and cellular immunogenicity and adverse events (AE) following two doses of COVID-19 approved vaccines. In 57 eligible studies reporting 7393 patients, clinical outcomes were rarely reported and rates of SARS-CoV-2 infection (range 0–11.9%), symptomatic disease (0–2.7%), hospital admission (0–2.8%), or death (0–0.5%) were low. Seroconversion rates ranged from 38.1–99.1% across studies with the highest response rate in myeloproliferative diseases and the lowest in patients with chronic lymphocytic leukemia. Patients with B-cell depleting treatment had lower seroconversion rates as compared to other targeted treatments or chemotherapy. The vaccine-induced T-cell response was rarely and heterogeneously reported (26.5–85.9%). Similarly, AEs were rarely reported (0–50.9% ≥1 AE, 0–7.5% ≥1 serious AE). In conclusion, HM patients present impaired humoral and cellular immune response to COVID-19 vaccination with disease and treatment specific response patterns. In light of the ongoing pandemic with the easing of mitigation strategies, new approaches to avert severe infection are urgently needed for this vulnerable patient population that responds poorly to current COVID-19 vaccine regimens.



中文翻译:

COVID-19 疫苗对血液系统恶性肿瘤患者的有效性、免疫原性和安全性:系统评价

由于疾病和治疗相关的免疫损伤,SARS-CoV-2 疫苗对血液系统恶性肿瘤 (HM) 患者的疗效似乎有限。我们对 2021 年 10 月 12 日以后在医学数据库中发表的前瞻性研究进行了系统评价,以评估两剂 COVID-19 批准疫苗后的临床疗效参数、体液和细胞免疫原性以及不良事件 (AE)。在报告 7393 名患者的 57 项符合条件的研究中,很少报告临床结果和 SARS-CoV-2 感染率(范围 0-11.9%)、症状性疾病(0-2.7%)、住院率(0-2.8%)或死亡(0–0.5%) 低。在骨髓增殖性疾病的反应率最高和慢性淋巴细胞白血病患者的反应率最低的研究中,血清转化率范围为 38.1-99.1%。与其他靶向治疗或化疗相比,接受 B 细胞耗竭治疗的患者的血清转化率较低。疫苗诱导的 T 细胞反应很少和异质性报道(26.5-85.9%)。同样,很少报告 AE(0–50.9% ≥1 AE,0–7.5% ≥1 严重 AE)。总之,HM 患者对 COVID-19 疫苗接种的体液和细胞免疫反应受损,具有疾病和治疗特异性反应模式。鉴于随着缓解策略的放松而持续流行,对于对当前 COVID-19 疫苗方案反应不佳的弱势患者群体,迫切需要新的方法来避免严重感染。疫苗诱导的 T 细胞反应很少见且异质性报道(26.5-85.9%)。同样,很少报告 AE(0–50.9% ≥1 AE,0–7.5% ≥1 严重 AE)。总之,HM 患者对 COVID-19 疫苗接种的体液和细胞免疫反应受损,具有疾病和治疗特异性反应模式。鉴于随着缓解策略的放松而持续流行,对于对当前 COVID-19 疫苗方案反应不佳的弱势患者群体,迫切需要新的方法来避免严重感染。疫苗诱导的 T 细胞反应很少见且异质性报道(26.5-85.9%)。同样,很少报告 AE(0–50.9% ≥1 AE,0–7.5% ≥1 严重 AE)。总之,HM 患者对 COVID-19 疫苗接种的体液和细胞免疫反应受损,具有疾病和治疗特异性反应模式。鉴于随着缓解策略的放松而持续流行,对于对当前 COVID-19 疫苗方案反应不佳的弱势患者群体,迫切需要新的方法来避免严重感染。

更新日期:2022-05-31
down
wechat
bug